#2 0 ,-/2 4 3 Toxicological Summary PFOS Dietary Acute Northern Bobwhite Study Test Substance: Perfluorooctanesulfonate (PFOS) Structure: 1-Octanesulfonic acid, 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-, potassium salt, CAS# 2795-39-3 Remarks: The test substance is a white powder (3M lot #217).

A X > 6 'I 8 S ^ Toxicological Summary PFOS Dietary Chronic Definitive Reproductive Study: Northern Bobwhite Test Substance: Perfluorooctanesulfonate (PFOS) Structure: 1-Octanesulfonic acid, 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro, potassium salt.

3M 55p Katherine E.

Ta~Wei F u 10/11/02 11:57 AM To: Katsunosuke Kitagawa/PO/DuPont@DuPont cc: Hidetaka Hiromatsu/PO/DuPont@DuPont Subject Re: C-8 in the AirD Kitagawa-san, It is rather complicated to explain on paper concerning the C EG issue.

AR226-2358 m DRAFT PHASE II MONITORING/SAMPLING WORK PLAN DUPONT WASHINGTON WORKS SITE WASHINGTON, WEST VIRGINIA Date: March 2004 Project N o.: 507423 18983990.04006 18983992.04006 lig sr A CORPORATE REMEDIATION GROUP An Alliance between DuPont and URS Diamond Barley Mill Plaza, Building 27 Wilmington, Delaware 19805 EXP000387 Draft Document Do Not Cite or Quote, March 30, 2004 Draft Phase II Monitoring/Sampling W ork Plan w TABLE OF CONTENTS Table o f Contents 1.0 Introduction 2.0 Background Information 3.0 Air M odeling V erification S tu dy................................................ 3.1 Phase II A ir M onitoring A ctiv ity ..................................... 3.1.1 A ir Sampling Events, Duration and Locations 3.1.2 Number o f S am p les.......................... -.................. 3.1.3 Sampling Equipment, Methods and Schedule. 3.1.4 Analytical M ethods............................................... 3.1.5 M eteorological M onitoring................. ............... 3.1.6 M eteorological D ata............................................ 3.1.7 M odel Selection and M ethodology................... 3.1.8 Receptor S election ............................................... 3.2 Progress Reports and R esu lts............................................ 4.0 Water M onitoring A ctiv ities....................................................................................... 4.1 Private W ater Sources....................................................................... ................ 4.1.1 W est Virginia: GIST Conclusions and Recommendations for W est Virginia Private Water Supply Sources............................... 4.1.2 W est Virginia: Private Water Supply Sources A ctiv ities........... 4.1.3 Ohio: GIST C onclusions and Recommendations for Ohio Private Water Supply S ources..................... ................................... 4.1.4 Ohio: Private W ater Supply Sources A ctivities........................... 4.2 Public W ater S ources.........................................................................-.............. 4.2.1 W est Virginia: GIST Conclusions and Recommendations for W est Virginia Public Water Supply Sources............................... 4.2.2 W est Virginia Public Water Supply Sources A ctiv ities............ 4.2.3 Ohio: GIST Conclusions and Recommendations for Ohio Public W ater Supply S ources.......................................................... 4.2.4 O hio Public W ater Supply Sources A ctivities............................. 4.2.5 Ohio: OEPA Recommended W ell Installation at Little Hocking W ater A ssociation W ell F ield ........................................ 5.0 Surface Water and Groundwater M onitoring..... 6.0 Surface S oil/B iota (V egetation) Sam pling......... 7.0 Schedule and R eporting.......................................... 8.0 R eferences.................................................................. 5 5 5 5 6 6 7 7 8 8 8 .9 .9 .9 10 11 12 13 13 13 14 14 15 EXP000388 2004W orkP lan 4.do c Wilmington, DE Draft Document Do Not Cite or Quote, March 30, 2004 Draft Phase II Monitoring/Sampling W o rt Plan Table o f Contents Table 1 Table 2 Table 3 .

2195 Front Street Logan, OH 4313S ONeEFftState rfOhio Environm ental Protection Agency Southeast District Office TELE: (740) 385-8501 FAX: (740) 385-6480 A R 2 2 6 -2 6 0 8 Bob Taft, Governor Christopher Jones, Director July 8,2002 Mr.

1anraster Laboratories 2 4 2 5 N e w Holland Pike * Lancaster, PA 1 7 601 AR226-2726 Analysis #0813FC - Revision 01 Supersedes Date: None Effective Date: 0 3 2001 Page 1 of 11 Extraction of Low Level FC-143 in Water and Wastewater Reference: Low Level Determination of FC-143 in Water, CH2M Hill, Inc., Oc Cross Reference: The following procedure is cross-referenced in this docun enL SOP-OE-001, "Glassware Cleaning for O r g a n i Scope: This method is designed to extract bC -U o lamrffbnium perfluorooctanoate) from water.

NORTHERN KENTUCKY OFFICE SUITE 340 1717 DIXIE HIGHWAY COVINGTON, KENTUCKY 41011-4704 606-331-2838 tip IO 513-381-2838 FAX: 513-381-6613 1 J DAYTON, OHIO OFFICE * SUITE 900 110 NORTH MAIN STREET DAYTON, OHIO 45402-1786 937-228-2838 FAX: 937-228-2816 Robert A.

ATSttCn:A SDeocctuiomne8n(et)P/FroYcIessing Center Attachment 1 P-1 P-1 July 28,2006 Page 4 of 5 M Z26 _373J- Acronym codefor Tables 1 and 2 In Tables 1 and 2, the following acronyms are used: acronym meaning CW FW WW DuPont Chambers Works facility in Deepwater, New Jersey DuPont Fayetteville Works facility in Fayetteville, North Carolina DuPont Washington Works facility in Parkersburg, West Virginia PPPFFFHPBeAxAA PFHpA PPPPFFFFOUDNnAAAA PFDoA PFBS PPPFFFOHOSxSSA PPeerrfflluuoorroobpuentatannooicicaacicdid Perfluorohexanoic acid Perfluoroheptanoic acid Perfluorooctanoic acid Perfluorononanoic acid Perfluorodecanoic acid Perfluorotmdecanoic acid PPPeeerrrfffllluuuooorrrooobhdueoxtdaaennceaenssuoulilfcfooanncaaitdtee Perfluorooctane sulfonate Perfluorooctane sulfonamide Attachment 1 Spaed Matrix Lab Blank 1 cw # P % cw p 3 cw n m 34 CW (DUPLICATE) c w v 5 cw i cw < P * CW 7 cw qp ( CW WG18817-102 Y2 WG18817-101 Y1 L8789-1 Y1 LB789-2 Y1 L87B9-3 Y1 WG18817-103Y1 L8789-4 Y1 L8789-5 Y1 LB789-5 Y1 LB789-6 Y1 L8789-7 Y1 L8789-8 Y1 % Recovery ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL WQ18817 W Q 18817 WQ18817 WQ18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 PFBA 81.2 ND ND ND ND ND ND <1.44 <1.44 <1.44 NO ND PFPeA 79.0 ND ND ND ND ND ND ND NO ND ND ND PFHxA 85.8 ND 1.82 ND <0.900 <0.900 ND ND ND <0.900 ND <0.900 PFHpA 83.5 ND ND ND ND ND <1.41 3.71 3.71 11.7 6.91 ND PFO A 110 ND 7.71 9.72 24.1 21.6 42.8 13.4 13.4 111 56.7 26.6 PFNA 11B ND 4.28 2.90 7.10 6.78 18.3 4.22 4.22 53.1 29.2 2.37 PFDA 115 ND <1.06 <1.08 1.64 1.51 8.47 1.82 1.82 13.5 7.47 <1.08 PFUnA 128 ND <1.02 <1.02 2.37 2.60 1.70 <1.02 <1.02 3.99 1.55 ND PFDoA 60.9 ND ND ND <0.600 <0 600 0.943 <0.600 <0.600 1.10 0.737 ND PFBS 94.8 ND ND ND ND ND ND ND ND ND ND ND PFHxS 104 ND <3.72 <3.72 39.1 33.5 <3.72 <3.72 <3.72 4.28 <3.72 3.81 PFOS 112 ND 51.1 35.3 68.2 58.0 25.7 35.0 36.0 39.0 53.8 36.8 PFO SA 73.5 ND ND ND ND ND ND ND ND NO ND ND Attachment 1 PFBA PFPeA PFHxA PFHpA PFOA PFNA PFDA PFUnA PFDoA PFBS PFHxS PFOS PFOSA tp // CW ^ k F w t f f lV L8789-9 Y1 LS789-10Y1 L8789-11 Y1 ngftnL ngAnL WG1B817 WG18817 ngAmL WG18817 ND ND NO ND ND ND ND ND ND NO 1.48 ND 12.9 13.0 28.3 <1.53 3.97 2.28 ND <1.08 <1.08 ND <1.02 <1.02 ND ND ND ND ND ND <3.72 <3.72 6.64 30.7 46.9 37.2 ND ND ND t-2.

P-1 TSCADocument Processing Center Attn: Section 8(eVFYI yf fL 7 - 7 i- 3 7 3 S Attachment 2 p- 2 July 28,2006 Page 5 of 5 Axys Analytical Services Laboratory - Form 1A and Form 2 (2 pages) P-2 P-3 s r.......... 7 ' "r *'*.".* *'"' ______;______

MICHAEL i .

Diabetes Care Publish Ahead of Print, published online December 29, 2008 Perjluoroalkyl chemicals, glucose homeostasis and metabolic syndrome Association Among Serum Perfluoroalkyl Chemicals, Glucose Homeostasis and Metabolic Syndrome in Adolescents and Adults Running title: PeruofGplkyl chemicals, glucose homeostasis and metabolic syndrome Chien-Yu Lin1-2'3, MD, MPH; pau-Chung Chen2, MD, PhD; Yu-Chuan Lin2' 4, MD; Lian-Yu Lin, MD, PhD5 1, Department of Internal iMedicine o f Nephrology, En Chu Kong Hospital, Taipei County, Taiwan 2, Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan 3, School o f Medicine, Fu Jen Catholic University, Taipei County, Taiwan 4, Department of Pediatrics, Taipei City H ospita*>Zhongxiao Branch, Taipei Taiwan 5, Department of Internal Medicine o f Cardiology, National Taiwan University Hospital, Taipei, Taiwan Corresponding author: Lian-Yu Lin E-mail: hspenosf5tvahoo.com.tw Submitted 3 October 2008 and accepted 17 December 2008.

SEVERN TRENT LABORATORIES ANALYTICAL REPORT JOB NUMBER: 244434 Prepared For: Weston Solutions, Inc. 1400 Weston Way Building 5-2 West Chester, PA 19380-1499 Project: Confidential Decatur - FC Investigation Attention: Jai Kesari Date: 03/06/2006 Signature Name: Richard C.

3M General Offices 3M Center St.

/lRs*_ \!